Neuroimaging contrast agents in ophthalmology

Survey of Ophthalmology

Volumn 45, Issue 3, 2000, Pages 237-253

  Lee, Andrew G ^a   Hayman, L Anne ^b,c   Ross, Andrew W ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Department of Radiology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse effects; Computed tomography; Contrast agents; Gadolinium; Imaging studies; Iodinated contrast agents; Magnetic resonance imaging; Neuroimaging; Toxicity

Indexed keywords

CONTRAST MEDIUM; DIATRIZOATE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; IODINATED CONTRAST MEDIUM; IOFENDYLATE; IOHEXOL; IONIC CONTRAST MEDIUM; IOPAMIDOL; IOVERSOL; IOXAGLIC ACID; MEGLUMINE; MEGLUMINE DIATRIZOATE; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; MEGLUMINE IOTALAMATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; METRIZAMIDE; NONIONIC CONTRAST MEDIUM;

ANAPHYLACTIC SHOCK; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; DEATH; DIAGNOSTIC ACCURACY; EYE DISEASE; FEMORAL ANGIOGRAPHY; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROOPHTHALMOLOGY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SICKLE CELL CRISIS; SKIN DISEASE; THYROTOXICOSIS;

EID: 0033696444     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(00)00152-1     Document Type: Article

References (162)

1. Contrast issues in brain tumor imaging
2. Triiodothyronine thyrotoxicosis following iodide ingestion: A case report
3. The etiology of contrast medium reactions
4. Rationale for the use of contrast media in MR imaging
5. Acute renal failure due to radio-contrast agents
6. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience
7. Focal epileptic activity following intravenous contrast material injection in patients with metastatic brain disease
8. Magnetization transfer contrast: Its utility as a technique and its application to central nervous system pathology
9. Efficacy of gadoteridol for contrast-enhanced magnetic resonance imaging in children
10. Post-angiographic blindness in a patient with sickle cell disease
11. Inadvertent IV administration of gadopentate demeglumine during early pregnancy
12. Clinical comparison of three contrast agents used in cerebral angiography
13. Clinical summary and conclusions: Ionic versus nonionic contrast agents and their effects on blood components
14. Safety and efficacy of iodinated contrast agents
15. Adverse events with radiographic contrast agents: Results of the SCVIR Contrast Agent Registry
16. Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection
17. Glomerular filtration rate estimated after multiple injections of contrast medium during angiography
18. Gd-DTPA in clinical MR of the brain: 1. Intra-axial lesions
19. The case strengthens for allergy to contrast media
20. Magnetic resonance imaging contrast agents: Theory and application to the central nervous system
21. Radiocontrast-induced acute renal failure: A clinical and pathophysiologic review
22. Contrast agents in neuroimaging
23. Gadolinium as a contrast agent for NMR
24. The prospective evaluation of Gd-DTPA in 225 consecutive cranial cases: Adverse reactions and diagnostic value
25. Contrast agents in magnetic resonance imaging
26. Magnetic resonance contrast agents for neuroimaging. Safety issues
27. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent
28. Predicting angiography-induced acute renal function impairment: Clinical risk model
29. Renal failure following radiologic procedures
30. Hemolytic anemia associated with a radiopaque contrast agent in a patient with hemoglobin SC disease
31. Contrast agents, red cells, coagulation, and the angiographer
32. Iodinated intravascular contrast agents: A review
33. Risk of acute renal failure following angiography in the elderly: A case report
34. Nephrotoxicity from angiographic contrast material. A prospective study
35. Comparative safety of intracarotid iopamidol, iothalamate, meglumine and diatrizoate meglumine for cerebral angiography
36. Researchers report severe reaction to MR contrast agent
37. Renal failure after major angiography can be avoided with hydration
38. Neurotoxicity of metrizamide
39. Gadopentetate dimeglumine-enhanced MR of the brain: Clinical utility and safety in patients younger than two years of age
40. Gd-DTPA-enhanced cranial MR imaging in children: Initial clinical experience and recommendations for its use
41. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood brain barrier
42. Choices for intravascular contrast agents
43. Iodide-induced thyrotoxicosis
44. Transient reduction in renal function following arteriography: A radionuclide study
45. Acute renal failure after arteriography with a gadolinium-based contrast agent
46. Thromboembolic events and nonionic contrast
47. Hypertensive crisis as a result of adrenal venography in a patient with pheochromocytoma
48. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials
49. Development of contrast media for magnetic resonance imaging
50. Acute renal dysfunction after major arteriography
51. Acute renal dysfunction in high-risk patients after angiography: Comparison of ionic and nonionic contrast media
52. Renal toxicity of radiological contrast media
53. Adverse reactions to radiographic contrast material
54. Gadodiamide injection: Nonionic gadolinium chelate for MR imaging of the brain and spine - Phase II-III clinical trial
55. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients
56. Effects of angiography on renal function and histology in infants and piglets
57. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease
58. Generalized seizure after i.v. administration of gadopentetate dimeglumine
59. Gadopentetate dimeglumine in craniospinal magnetic resonance imaging: Common uses and some potential pitfalls
60. Contrast nephropathy
61. Contrast media-induced blood-brain barrier damage. Potentiation by hypertension
62. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent
63. Implementing HCFA guidelines on appropriate use of nonionic contrast agents for diagnostic arteriography: Effects on complication rates and management costs
64. Neurotoxic complications of contrast computed tomography in children
65. Intrathecal toxicity of iohexol vs. metrizamide: Survey and current state
66. Triple-dose versus standard-dose gadopentetate dimeglumine: A randomized study in 199 patients
67. Increased detection of intracranial metastases with intravenous Gd-DTPA
68. Basic physics of MR contrast agents and maximization of image contrast
69. Anaphylactoid reactions to iodinated contrast media. Hospital Practice (Office Edition)
70. Cerebral angiography with iohexol. A comparison with metrizamide in man
71. Transient global amnesia and cortical blindness after vertebral angiography: Further evidence for the role of arterial spasm
72. The emerging role of magnetic resonance angiography in the management of patients with third cranial nerve palsy
73. Safety considerations in MR imaging
74. Rapid bolus injection of gadopentate dimeglumine: Absence of side effects in normal volunteers
75. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media
76. Contrast agents for myelography: Clinical and radiological evaluation of Amipaque and Pantopaque
77. Cortical blindness after coronary angiography: A rare but reversible complication
78. Low-osmolality versus high-osmolality contrast material
79. Routine contrast enhancement for cranial magnetic resonance imaging: An analysis of its diagnostic value in adults
80. Optimization of low-osmolality contrast media for cranial CT: A dose comparison of two contrast agents
81. Low incidence of renal failure after angiography
82. The incidence of contrast medium induced acute tubular necrosis following arteriography
83. Mechanisms of severe, immediate reactions to iodinated contrast material
84. Radiocontrast-associated renal dysfunction: Incidence and risk factors
85. Extravasations of radiographic contrast material in the upper extremity
86. Severe anaphylactoid reaction to Gd-DTPA
87. Contrast agent-induced emesis
88. Stability of gadolinium complexes in vitro and in vivo
89. Renal dysfunction after arteriography
90. Multiple myeloma and contrast media
91. Preston M. Hickey memorial lecture. Ionic and nonionic iodinated contrast media: Evolution and strategies for use
92. Renal failure after radiological contrast media
93. Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS
94. Cerebral angiography with the non-ionic water-soluble contrast medium iohexol and meglumine-Ca-metrizoate. A randomized double blind parallel study in man
95. A double-blind clinical study comparing tolerability, safety, and efficacy of Hexabrix and Renografin-76 for intravenous subtraction angiography
96. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors
97. Contrast media-related thromboembolic risks: Effects of blood mixed with contrast media in contact with angiographic catheters
98. Biodistribution and toxicity of MR imaging contrast media
99. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study
100. Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures
101. Clinical trial of Iohexol vs. Conray 60 for cerebral angiography
102. The use of iopamidol in cerebral angiography
103. Plasma catecholamines in pheochromocytoma: Effect of urographic contrast media
104. Safety and efficacy of sodium and meglumine ioxaglate (Hexabrix) and Hypaque M60% in contrast-enhanced computed cranial tomographic scanning. A double-blind clinical study
105. Angiographic contrast agent-induced acute hemolysis in a patient with hemoglobin SC disease
106. The effect of ionic and nonionic contrast media on the sickling phenomenon
107. Anticoagulant effects of contrast materials: In vitro study of iohexol, ioxaglate, and diatrizoate
108. Neurotoxic effects of gadopentetate dimeglumine: Behavioral disturbance and morphology after intracerebroventricular injection in rats
109. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats
110. European Magnetic Resonance Forum Proceedings. New developments in contrast agent research 5th special topic seminar on magnetic resonance contrast agents
111. Nonionic contrast media in radiology. Procedural considerations
112. Effect on fetal mouse development of exposure to MR imaging and gadopentetate dimeglumine
113. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: Toxicity and MR findings
114. Effects of gadopentetate dimeglumine administration after osmotic blood- brain barrier disruption: Toxicity and MR imaging findings
115. Iodinated radiographic contrast media: Comparison of low-osmolar with conventional ionic agents
116. Magnetic resonance imaging contrast agents
117. Clinical safety and efficacy of gadoteridol: A study in 411 patients with suspected intracranial and spinal disease
118. Paramagnetic NMR contrast agents. Development and evaluation
119. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption
120. Gd-HP-DO3A in clinical MR imaging of the brain
121. Principles of contrast enhancement in the evaluation of brain diseases: An overview
122. Work in progress: Potential oral and intravenous paramagnetic NMR contrast agents
123. Update: Safety, new applications, new MR agents
124. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: Evaluation in patients with cerebral lesions
125. Case of anaphylaxis and four cases of allergic reaction following Gd- DTPA administration
126. Aggravation of thyrotoxicosis by an iodinated contrast medium
127. Generalized motor seizure following metrizamide cisternography
128. Local toxicity of metrizamide on intravascular injection. Effect on kidney, liver and blood-brain barrier
129. Excretion of gadopentetate dimeglumine in human breast milk
130. Contrast nephrotoxicity: A randomized controlled trial of a nonionic and an ionic radiographic contrast agent
131. Clinical experience with routine Gd-DTPA administration for MR imaging of the brain
132. Efficacy and safety of digital subtraction angiography with special reference to contrast agents
133. Death following intravascular administration of contrast media
134. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey
135. T4-thyroid storm after CT-scan with iodinated contrast medium
136. The use of iohexol in patients with previous reactions to ionic contrast material. A multicenter clinical trial
137. High-dose iohexol myelography
138. Summary of preclinical safety evaluation of gadoteridol injection
139. Contrast agents in functional MR imaging
140. Safety of ionic and nonionic contrast media
141. Ionic versus nonionic contrast use
142. Conventional or low osmolality: Picking the right contrast media
143. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine
144. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system
145. Multicenter study of gadopentetate dimeglumine as an MR contrast agent: Evaluation in patients with spinal tumors
146. Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier
147. Intravascular contrast media: Can we justify the continued use of ionic contrast agents?
148. Anaphylactoid reactions to i.v. gadopentetate dimeglumine
149. Comparison of iohexol 300 mg I/ml and Hexabrix 320 mg I/ml in central angiography. A double-blind trial
150. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent
151. Life-threatening hypotensive reactions to contrast media administration: Comparison of pharmacologic and fluid therapy
152. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent
153. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent
154. Pharmacokinetics of GdDTPA/dimeglumine after injection into healthy volunteers
155. Severe anaphylactoid reaction after i.v. Gd-DTPA
156. The adverse effects of angiographic radiocontrast media
157. Magnetic resonance imaging and computed tomography. Ophthalmology Monographs 6
158. Safety of ionic and nonionic contrast media
159. Safer, more expensive iodinated contrast agents: How do we decide?
160. Utility of magnetic resonance contrast agents in routine cranial imaging. Case study of an evaluative method
161. Influence of arteriographic contrast media on the Na+/Ca++-ratio in blood
162. Iodinated contrast agents in neuroradiology